Soft tissue sarcomas in children

Seminars in Surgical Oncology

Volumn 16, Issue 2, 1999, Pages 121-143

  Pappo, Alberto S ^a,d   Parham, David M ^b   Rao, Bhaskar N ^a   Lobe, Thom E ^a,c  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b ARKANSAS CHILDREN S HOSPITAL   (United States)

^c UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^d UNIVERSITY OF TENNESSEE COLLEGE OF MEDICINE   (United States)

Author keywords

Adolescent; Amputation; Brachytherapy; Child; Combined antineoplastic agents; Combined modality therapy; Congenital abnormalities; Cyelophosphamide; Dacarba zine; Dactinomycin; Differential diagnosis; Disease free survival; Doxorubicin; Etoposide; Extremities; Ifosfamide; Incidence; Infant; Li Fraumeni syndrome; Local neoplasm recurrence; Lymph nodes; Melphalan; Neoplasm metastasis; Neoplasm staging; Neurofibromatosis 1; P53 gene; Polymerase chain reaction; Preschool child; Prognosis; Radiation dosage; Rhabdomyosarcoma; Risk; Sarcoma; Soft tissue neoplasms; Survival rate; Topotecan; Translocation; Vincristine

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; CYCLOPHOSPHAMIDE; DACARBAZINE; DACTINOMYCIN; DOXORUBICIN; ETOPOSIDE; IFOSFAMIDE; MELPHALAN; PROTEIN P53; TOPOTECAN; VINCRISTINE;

ARTICLE; CANCER CLASSIFICATION; CANCER INVASION; CANCER RECURRENCE; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; CHILD; CHILDHOOD CANCER; HISTOPATHOLOGY; HUMAN; MULTIMODALITY CANCER THERAPY; NEUROFIBROMATOSIS; PRIORITY JOURNAL; PROGNOSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA TRANSLATION; SOFT TISSUE SARCOMA;

EID: 0032931514     PISSN: 87560437     EISSN: None     Source Type: Journal    
DOI: 10.1002/(sici)1098-2388(199903)16:2<121::aid-ssu5>3.0.co;2-%23     Document Type: Article

References (127)

1. Newton WA Jr, Soule EH, Hamoudi AB, et al: Histopathology of childhood sarcomas, Intergroup Rhabdomyosarcoma Studies I and II: clinicopathologic correlation. J Clin Oncol 1988;6:67-75.
2. Enzinger FM, Weiss SW: "Soft tissue tumors". 3rd ed. St. Louis: Mosby, 1995.
3. Madden NP, Spicer RD, Allibone EB, Lewis IJ: Spontaneous regression of neonatal fibrosarcoma. Br J Cancer - Suppl 1992;18:S72-S75.
4. rd, et al: Nonrhabdomyosarcomatous soft tissue sarcomas of childhood: formulation of a simplified system for grading. Mod Pathol 1995;8:705-710.
5. Bauernhofer T, Stoger H, Schmid M, et al: Sequential treatment of recurrent mesenteric desmoid tumor [Review]. Cancer 1996;77: 1061-1065.
6. Dominguez-Malagon HR, Alfeiran-RuizA, Chavarria-Xicotencatl P, Duran-Hernandez MS: Clinical and cellular effects of colchicine in fibromatosis. Cancer 1992;69:2478-2483.
7. Taylor SR, Nunez C. Fine-needle aspiration biopsy in a pediatric population. Report of 64 consecutive cases. Cancer 1984;54:1449-1453.
8. Wexler LH, Helman LJ. Rhabdomyosarcoma and the undifferentiated sarcomas. In Pizzo PA, Poplack DG (eds): "Principles and practice of pediatric oncology". Philadelphia: Lippincott-Raven; 1997, p. 799-829.
9. Miller RW, Young JL Jr, Novakovic B: Childhood cancer. Cancer 1995; 75(1 Suppl):395-405.
10. Pappo AS, Shapiro DN, Crist WM, Maurer HM: Biology and therapy of pediatric rhabdomyosarcoma [Review]. J Clin Oncol 1995;13:2123-2139.
11. Rao BN: Nonrhabdomyosarcoma in children: prognostic factors influencing survival. Semin Surg Oncol 1993;9:524-531.
12. Miser JS, Triche TJ, Kinsella TJ, Pritchard DJ: Other soft tissue sarcomas of childhood. In Pizzo PA, Poplack DG (eds) "Principles and practice of pediatric oncology". Philadelphia: Lippincott-Raven; 1997, p. 865-888.
13. Crist W, Gehan EA, Ragab AH, et al: The Third Intergroup Rhabdomyosarcoma Study. J Clin Oncol 1995;13:610-630.
14. Maurer HM, Beltangady M, Gehan EA, et al: The Intergroup Rhabdomyosarcoma Study-I. A final report. Cancer 1988;61:209-220.
15. Maurer HM, Gehan EA, Beltangady M, et al: The Intergroup Rhabdomyosarcoma Study-II. Cancer 1993;71:1904-1922.
16. Grufferman S, Schwartz AG, Ruymann FB, Maurer HM: Parents' use of cocaine and marijuana and increased risk of rhabdomyosarcoma in their children. Cancer Causes Control 1992;4:217-224.
17. Grufferman S, Wang HH, DeLong ER, et al: Environmental factors in the etiology of rhabdomyosarcoma in childhood. J Natl Cancer Inst 1982;68:107-113.
18. Ghali MH, Yoo KY, Flannery JT, Dubrow R: Association between childhood rhabdomyosarcoma and maternal history of stillbirths. Int J Cancer 1992;50:365-368.
19. Ruymann FB, Maddux HR, Ragab A, et al: Congenital anomalies associated with rhabdomyosarcoma: an autopsy study of 115 cases. A report from the Intergroup Rhabdomyosarcoma Study Committee [Review]. Med Pediatr Oncol 1988;16:33-39.
20. Yang P, Grufferman S, Khoury MJ, et al: Association of childhood rhabdomyosarcoma with neurofibromatosis type 1 and birth defects. Genet Epidemiol 1995;12:467-474.
21. Malkin D: p53 and the Li-Fraumeni syndrome [Review]. Cancer Genet Cytogen 1993;66:83-92.
22. Hartley AL, Birch JM, Blair V, et al: Patterns of cancer in the families of children with soft tissue sarcoma. Cancer 1993;72:923-930.
23. Diller L, Sexsmith E, Gottlieb A, et al: Germline p53 mutations are frequently detected in young children with rhabdomyosarcoma. J Clin Invest 1995;95:1606-1611.
24. Tapscott SJ, Weintraub H: MyoD and the regulation of myogenesis by helix-loop-helix proteins [Review]. J Clin Invest 1991;87:1133-1138.
25. Dias P, Parham D, Shapiro DN, et al: Myogenic regulatory protein (MyoD1) expression in childhood solid tumors: diagnostic utility in rhabdomyosarcoma. Am J Pathol 1990; 137:1283-1291.
26. Horn RC, Enterline HT: Rhabdomyosarcoma: a clincopathological study and classification of 39 cases. Cancer 1958;11:181-191.
27. Scrable H, Witte D, Shimada H, et al: Molecular differential pathology of rhabdomyosarcoma. Genes Chromosomes Cancer 1989;1:23-35.
28. Davis RJ, D'Cruz CM, Lovel MA, et al: Fusion of PAX7 to FKHR by the variant t(1;13)(p36;q14) translocation in alveolar rhab-domyosarcoma. Cancer Res 1994;54:2869-2872.
29. Kelly KM, Womer RB, Sorensen PH, et al: Common and variant gene fusions predict distinct clinical phenotype in rhabdomyosarcoma. J Clin Oncol 1997;15:1831-1836.
30. Downing JR, Khandekhar A, Shurtleff SA, et al: A multiplex RT-PCR assay for the differential diagnosis of alveolar rhabdomyosarcoma and Ewing's sarcoma. Am J Pathol 1995;146:626-634.
31. Felix CA, Kappel CC, Mitsudomi T, et al: Frequency and diversity of p53 mutations in childhood rhabdomyosarcoma. Cancer Res 1992;52:2243-2247.
32. Pappo AS, Shapiro DN, Cris WM. Rhabdomyosarcoma. Biology and treatment [Review].Pediatr Clin North Am 1997;44:953-972.
33. Shapiro DN, Parham DM, Douglass EC, et al: Relationship of tumor-cell ploidy to histologic subtype and treatment outcome in children and adolescents with unresectable rhabdomyosarcoma [published erratum appears in J Clin Oncol 1991;9:893]. J Clin Oncol 1991;9:159-166.
34. Lawrence W Jr, Gehan EA, Hays DM, et al: Prognostic significance of staging factors of the UICC staging system in childhood rhabdomyosarcoma: a report from the Intergroup Rhabdomyosarcoma Study (IRS-II). J Clin Oncol 1987;5:46-54.
35. Rodary C, Gehan EA, Flamant F, et al: Prognostic factors in 951 nonmetastatic rhabdomyosarcoma in children: a report from the International Rhabdomyosarcoma Workshop. Med Pediatr Oncol 1991;19:89-95.
36. Andrassy RJ, Corpron CA, Hays D, et al: Extremity sarcomas: an analysis of prognostic factors from the Intergroup Rhabdomyosarcoma Study III. J Pediatr Surg 1996;31:191-196.
37. Lawrence W Jr, Anderson JR, Gehan EA, Maurer H; Pretreatment TNM staging of childhood rhabdomyosarcoma: a report of the Intergroup Rhabdomyosarcoma Study Group. Cancer 1997;80: 1165-1170.
38. Crist WM, Garnsey L, Beltangady MS, et al: Prognosis in children with rhabdomyosarcoma: a report of the Intergroup Rhabdomyosarcoma Studies I and II.J Clin Oncol 1990;8:443-452.
39. Kodet R, Newton WA Jr, Hamoudi AB, et al: Orbital rhabdomyosarcomas and related tumors in childhood: relationship of morphology to prognosis - an Intergroup Rhabdomyosarcoma Study. Med Pediatr Oncol 1997;29:51-60.
40. Anderson JR, Ruby E, Link M, et al: Identification of a favorable subset of patients (pts) with metastatic (MET) rhabdomyosarcoma (RMS): a report from the Intergroup Rhabdomyosarcoma Study Group (IRSG) [Abstract]. Proc Am Soc Clin Oncol 1997; 16:510a (#1836).
41. Anderson JR, Link M, Arndt C, Maurer H: Prognostic factors defining risk categories for treatment of rhabdomyosarcoma (RMS) patients (PTS) on Intergroup Rhabdomyosarcoma Study (IRS) V. In Third International Congress on Soft Tissue Sarcoma in Children and Adolescents book of abstracts; 1997 April 30 - May 3; Stuttgart, Stuttgart, Germany; 1997. p. 57 (Abstract #O-CT-1).
42. Lawrence W Jr, Jegge G, Foote FW Jr: Embryonal rhabdomyosarcoma. A clinicopathological study. Cancer 1964;17:361-376.
43. Pinkel D, Pickren J: Rhabdomyosarcoma in children. JAMA 1961;175:293-298.
44. Flamant F, Hill C: The improvement in survival associated with combined chemotherapy in childhood rhabdomyosarcoma. Cancer 1984;53:2417-242121.
45. Donaldson SS: The value of adjuvant chemotherapy in the management of sarcomas in children [Review]. Cancer 1985;55:2184-2197.
46. Green DM, Jaffe N: Progress and controversy in the treatment of childhood rhabdomyosarcoma [Review]. Cancer Treat Rev 1978;5:7-27.
47. O'Bryan RM, Luce JK, Talley RW, et al: Phase II evaluation of adriamycin in human neoplasia. Cancer 1973;32:1-8.
48. Sutow WW: Vincristine (NSC-67574) therapy for malignant solid tumors in children (except Wilms' tumor). Cancer Chemother Rep - Part 1 1968;52:485-457.
49. Sutow WW. Cyclophosphamide (NSC-26271) in Wilms, tumor and rhabdomyosarcoma. Cancer Chemother Rep - Part 1 1967;51:407-409.
50. rd: The effect of actinomycin D on childhood neoplasms. Am J Dis Child 1960;99: 628-635.
51. Pratt CB, Hustu HO, Fleming ID, Pinkel D: Coordinated treatment of childhood rhabdomyosarcoma with surgery, radiotherapy, and combination chemotherapy. Cancer Res 1972;32:606-610.
52. Wilbur JR: Combination chemotherapy for embryonal rhabdomyosarcoma. Cancer Chemother Rep - Part 1 1974;58:281-284.
53. Heyn RM, Holland R, Newton WA Jr, et al: The role of combined chemotherapy in the treatment of rhabdomyosarcoma in children. Cancer 1974;34:2128-2142.
54. Arndt C, Tefft M, Gehan E, et al: A feasibility, toxicity, and early response study of etoposide, ifosfamide, and vincristine for the treatment of children with rhabdomyosarcoma: a report from the Intergroup 35 Rhabdomyosarcoma Study (1RS) IV pilot study. J Pediatr Hematol Oncol 1997;19:124-129.
55. Onega JA, Donaldson SS, Ivy SP, et al: Venooclusive disease of the liver after chemotherapy with vincristine, actinomycin D, and cyclophosphamide for the treatment of rhabdomyosarcoma. Cancer 1997;79:2435-2439.
56. Ruymann F, Crist W, Wiene E, et al: Comparison of Iwo doublet chemotherapy regimens and conventional radiotherapy in metastatic rhabdomyosarcoma: improved overall survival using ifosfamide/etoposide comapred to vincristine/melphalan in IRSG-IV [Abstract]. Proc Am Soc Clin Oncol 1997;16:521a (#1874).
57. Vietti T, Crist W, Ruby E, et al: Topotecan window in patients with rhabdomyosarcoma (RMS): an IRSG study [Abstract]. Proc Am Soc Clin Oncol 1997;16:510a (#1837).
58. Raney BR Jr, Gehan EA, Hays DM, et al: Primary chemotherapy with or without radiation therapy and/or surgery for children with localized sarcomas of the bladder, prostate, vagina, uterus, and cervix. A comparison of results in Intergroup Rhabdomyosarcoma Studies I and II. Cancer 1990;66:2072-2081.
59. Hays DM: Bladder/prostate rhabdomyosarcoma: results of the multi-institutional trials of the Intergroup Rhabdomyosarcoma Study [Review]. Semin Surg Oncol 1993;9:520-523.
60. Tefft M, Fernandez C, Donaldson M, et al: Incidence of meningeal involvement by rhabdomyosarcoma of the head and neck in children: a report by the Intergroup Rhabdomyosarcoma Study (IRS) [Review]. Cancer 1978;42:253-258.
61. Raney RB Jr, Tefft M, Newton WA, et al: Improved prognosis with intensive treatment of children with cranial soft tissue sarcomas arising in nonorbital parameningeal sites. A report from the Intergroup Rhabdomyosarcoma Study. Cancer 1987;59:147-155.
62. Ortega JA, Fryer C, Gehan E, et al: Efficacy of reducing tissue volume irradiation in children with cranial (CR) parameningeal (PM) rhabdomyosarcoma (RMS). A report for the Intergroup Rhabdomyosarcoma Study (IRS) III [Abstract]. Proc Am Soc Clin Oncol 1990;9:291 (#1147).
63. Fryer CJ, Wharam MD Jr, Donaldson SS, et al: Parameningeal rhabdomyosarcoma: a comparative analysis of IRS I, II, II and IV pilot (IV-P) with emphasis on changes in radiation volume [Abstract]. In Third International Congress on Soft Tissue Sarcoma in Children and Adolescents book of abstracts. 1997 April 30 - May 3; Stuttgart, Stuttgart, Germany; 1997. p. 8 (#O-WRA-2)
64. Wharam MD Jr, Anderson JR, Laurie F, et al: Failure-free survival for orbit rhabdomyosarcoma patients on Intergroup Rhabdomyosarcoma Study IV (IRS-IV) is improved compared to IRS-III [Abstract]. Proc Am Soc Clin Oncol 1997;16:518a.
65. Wiener E, Grier H, Breneman J, et al: Changing pattern of relapse with localized paratesticular rhabdomyosarcoma in the Intergroup Rhabdomyosarcoma Study (IRS) Group trials. Proc Am Soc Clin Oncol 1997;16:519a (#1865).
66. Raney B, Ensign LG, Foreman J, et al: Renal toxicity of ifosfamide in pilot regimens of the Intergroup Rhabdomyosarcoma Study for patients with gross residual tumor. Am J Pediatr Hematol Oncol 1994;16:286-295.
67. Raney B Jr, Heyn R, Hays DM, et al: Sequelae of treatment in 109 patients followed for 5 to 15 years after diagnosis of sarcoma of the bladder and prostate. A report from the Intergroup Rhabdomyosarcoma Study Committee. Cancer 1993; 71:2387-2394.
68. Raney B, Tefft M, Heyn R, et al: Ascending myelitis after intensive chemotherapy and radiation therapy in children with cranial parameningeal sarcoma. Cancer 1992;69:1498-1506.
69. Heyn R, Haeberlen V. Newton WA, et al: Second malignant neoplasms in children treated for rhabdomyosarcoma. The Intergroup Rhabdomyosarcoma Study. J Clin Oncol 1993;11:262-270.
70. Heyn R, Khan F, Ensign L, et al: Acute myeloid leukemia in patients treated for rhabdomyosarcoma with cyclophosphamide and low-dose etoposide on the Intergroup Rhabdomyosarcoma Study III: an interim report. Med Pediatr Oncol 1994;23:93-106.
71. Donaldson SS, Asmar L, Breneman J, et al: Hyperfractionated radiation in children with rhabdomyosarcoma - results of an Intergroup Rhabdomyosarcoma Pilot Study. Int J Radiat Oncol Biol Phys 1995;32:903-911.
72. Horowitz ME, Etcubanas E, Christensen ML, et al: Phase II testing of melphalan in children with newly diagnosed rhabdomyosarcoma: a model for anticancer drug development. J Clin Oncol 1988;6:308-314.
73. Pappo AS, Etcubanas E, Santana VM, et al: A phase II trial of ifosfamide in previously untreated children and adolescents with unresectable rhabdomyosarcoma. Cancer 1993; 71:2119-2125.
74. Houghton PJ, Chesire PJ, Myers L, et al: Evaluation of 9-dimethyaminomethyl-10-hydroxycamptothecin against xenografts derived from adult and childhood solid tumors. Cancer Chemother Pharmacol 1992;31:229-239.
75. Houghton PJ, Shapiro DN, Houghton JA. Rhabdomyosarcoma. From the laboratory to the clinic [Review]. Pediatr Clin North Am 1991;38:349-364.
76. Shapiro DN, Jones BG, Shapiro LH, et al: Antisense-mediated reduction in insulin-like growth factor-I receptor expression suppresses the malignant phenotype of a human alveolar rhabdomyosarcoma. J Clin Invest 1994;94:1235-1242.
77. Potter PM, Shapiro D, Dias P. Ribozyme-mediated cleavage of a fusion transcript specifically expressed in alveolar rhabdomyosarcoma [Abstract]. Proc Am Assoc Cancer Res 1994;35:530.
78. Chung EB, Enzinger FM: Infantile fibrosarcoma. Cancer 1976;38:729-739.
79. th annual cancer symposium program; 1994 March 17-20; Houston. Houston, Texas: SSO; 1994. Abstract #93.
80. Raney RB, Kollath J, Anderson J, et al: Late effects of therapy for patients with primary orbital rhabdomyosarcoma: a report from the Intergroup Rhabdomyosarcoma Study (IRS)-III, 1984-1991 [Abstract]. Med Pediatr Oncol 1997;29:425.
81. deCou JM, Rao BN, Parham DM, et al: Malignant peripheral nerve sheath tumors: the St. Jude Children's Research Hospital experience. Ann Surg Oncol 1995;2:524-529.
82. McClain KL, Leach CT, Jenson HB, et al: Association of Epstein-Barr virus with leiomyosarcomas in children with AIDS. N Engl J Med 1995;332:12-18.
83. Pappo AS, Fontanesi J, Luo X, et al: Synovial sarcoma in children and adolescents: the St Jude Children's Research Hospital experience. J Clin Oncol 1994;12:2360-2366.
84. Zalupski MM, Baker LH: Systemic adjuvant chemotherapy for soft tissue sarcomas [Review]. Hematol Oncol Clin North Am 1995;9:787-800.
85. Mertens WC, Bramwell VH: Adjuvant chemotherapy for soft tissue sarcomas [Review]. Hematol Oncol Clin North Am 1995;9:801-815.
86. Pratt CB, Maurer HM, Salzberg A, et al: Treatment of unresectable or metastatic pediatric soft tissue sarcomas with surgery, irradiation and chemotherapy: a Pediatric Oncology Group study. Med Pediatr Oncol 1998;30:201-209.
87. Demetri GD, Elias AD. Results of single-agent and combination chemotherapy for advanced stage soft tissue sarcomas. Implications for decision making in the clinic [Review]. Hematol Oncol Clin North Am 1995;9:765-783.
88. Rao BN: Present day concepts of thoracoscopy as a modality in pediatric cancer management. Int Surg 1997;82:123-126.
89. Brennan MF: Gordon Bell memorial lecture. Management of soft tissue sarcoma. Aust NZJ Surg 1990;60:419-428.
90. Lawrence W Jr, Neifeld JP: Soft tissue sarcomas [Review]. Curr Probl Surg 1989;2:753-827.
91. Pratt CB, Kun LE: "Soft tissue sarcomas of children". Boston: Kluwer:1993.
92. Heslin MJ, Lewis JJ, Woodruff JM, Brennan MF: Core needle biopsy for diagnosis of extremity soft tissue sarcoma. Ann Surg Oncol 1997;4:425-431.
93. Schwartz HS, Spengler DM: Needle tract recurrences after closed biopsy for sarcoma: three cases and review of the literature [Review]. Ann Surg Oncol 1997;4:228-236.
94. Rao BN, Etcubanas EE, Green AA: Present-day concepts in the management of sarcomas in children [Review]. Cancer Invest 1989;7:349-356.
95. Meterissian SH, Reilly JA Jr, Murphy A, et al: Soft-tissue sarcomas of the shoulder girdle: factors influencing local recurrence, distant metastases, and survival. Ann Surg Oncol 1995;2:530-536.
96. Valle AA, Kraybill WG. Management of soft tissue sarcomas of the extremity in adults [Review]. J Surg Oncol 1996;63:271-279.
97. Keus RB, Rutgers EJ, Ho GH, et al: Limb-sparing therapy of extremity soft tissue sarcomas: treatment outcome and long-term functional results. Eur J Cancer 1994;30A:1459-1463.
98. Wilson AN, Davis A, Bell RS, et al: Local control of soft tissue sarcoma of the extremity: the experience of a multidisciplinary sarcoma group with definitive surgery and radiotherapy. Eur J Cancer 1994;30A:746-751.
99. Brennan MF, Casper ES, Harrison LB, et al: The role of multi-modality therapy in soft-tissue sarcoma. Ann Surg 1991;214: 328-338.
100. Wiklund T, Huuhtanen R, Blomqvist C, et al: The importance of a multidisciplinary group in the treatment of soft tissue sarcomas. Eur J Cancer 1996; 32A:269-273.
101. Williard WC, Collin C, Casper ES, et al: The changing role of amputation for soft tissue sarcoma of the extremity in adults. Surg Gynecol Obstet 1992;175:389-396.
102. Rao BN, Santana VM, Parham D, et al: Pediatric nonrhabdomyosarcomas of the extremities. Influence of size, invasiveness, and grade on outcome [published erratum appears in Arch Surg 1992;127:264]. Arch Surg 1991;126:1490-1495.
103. Goodlad JR, Fletcher CD, Smith MA: Surgical resection of primary soft-tissue sarcoma: incidence of residual tumour in 95 patients needing re-excision after local resection. J Bone Joint Surg Br 1996;78:658-661.
104. Brennan MF: The enigma of local recurrence. The Society of Surgical Oncology. Ann Surg Oncol 1997;4:1-12.
105. Zornig C, Peiper M, Schroder S. Re-excision of soft tissue sarcoma after inadequate initial operation. Br J Surg 1995;82:278-279.
106. Karakousis CP, Proimakis C, Walsh DL: Primary soft tissue sarcoma of the extremities in adults. Br J Surg 1995;82:1208-1212.
107. Cheng EY, Dusenbery KE, Winters MR, Thompson RC. Soft tissue sarcomas: preoperative versus postoperative radiotherapy. J Surg Oncol 1996;61:90-99.
108. Frezza G, Barbieri E, Ammendolia I, et al: Surgery and radiation therapy in the treatment of soft tissue sarcomas of extremities. Ann Oncol 1992;3 Suppl 2:S93-S95.
109. Nag S, Olson T, Ruymann F, et al: High-dose-rate brachytherapy in childhood sarcomas: a local control strategy preserving bone growth and function. Med Pediatr Oncol 1995;25:463-469.
110. Fontanesi J, Pappo AS, Parham DM, et al: Role of irradiation in management of synovia sarcoma: St. Jude Children's Research Hospital Experience. Med Pediatr Oncol 1996;26:264-267.
111. Jaffe KA, Morris SG: Resection and reconstruction for soft-tissue sarcomas of the extremity [Review]. Orthop Clin North Am 1991;22:161-176.
112. Pitcher ME, Thomas JM: Functional compartmental resection for soft tissue sarcomas. Eur J Surg Oncol 1994;20:441-445.
113. Rydholm A, Gustafson P, Rooser B, et al: Limb-sparing surgery without radiotherapy based on anatomic location of soft tissue sarcoma. J Clin Oncol 1991;9:1757-1765.
114. Philippe PG, Rao BN, Rogers DA, et al: Sarcomas of the flexor fossae in children: is amputation necessary? J Pediatr Surg 1992;27:964-967.
115. Serpell JW, Ball AB, Robinson MH, et al: Factors influencing local recurrence and survival in patients with soft tissue sarcoma of the upper limb. Br J Surg 1991;78:1368-1372.
116. Gross E, Rao BN, Bowman L, et al: Outcome of treatment for pediatric sarcoma of the foot: a retrospective review over a 20-year period. J Pediatr Surg 1997;32:1181-1184.
117. Gross E, Rao BN, Pappo AS, et al: Soft tissue sarcoma of the hand in children: clinical outcome and management. J Pediatr Surg 1997;32:698-702.
118. Johnstone PA, Wexler LH, Venzon DJ, et al: Sarcomas of the hand and foot: analysis of local control and functional result with combined modality therapy in extremity preservation. Int J Radiat Oncol Biol Phys 1994;29:735-745.
119. Brien EW, Terek RM, Geer RJ, et al: Treatment of soft-tissue sarcomas of the hand. J Bone Joint Surg Am 1995;77:564-571.
120. Nielsen OS, Cummings B, O'Sullivan B, et al: Preoperative and postoperative irradiation of soft tissue sarcomas: effect on radiation field size. Int J Radiat Oncol Biol Phys 1991; 21:1595-1599.
121. Cionini L, Marzano S, Olmi P: Soft tissue sarcomas: experience with intraoperative brachytherapy in the conservative management. Ann Oncol 1992;3 2 Suppl:S63-S66.
122. Willett CG, Suit HD, Tepper JE, et al: Intraoperative electron beam radiation therapy for retroperitoneal soft tissue sarcoma. Cancer 1991;68:278-283.
123. Mazeron JJ, Suit HD. Lymph nodes as sites of metastasis from sarcomas of soft tissue [Review]. Cancer 1987;60:1800-1808.
124. Mandell L, Ghavimi F, LaQuaglia M, Exelby P. Prognostic significance of regional lymph node involvement in childhood extremity rhabdomyosarcoma. Med Pediatr Oncol 1990;18:466-471.
125. Karasek K, Constine LS, Rosier R. Sarcoma therapy: functional outcome and relationship to treatment parameters. Int J Radiat Oncol Biol Phys 1992;24:651-656.
126. Bell RS, O'Sullivan B, Davis A, et al: Functional outcome in patients treated with surgery and irradiation for soft tissue tumours. J Surg Oncol 1991;48:224-231.
127. Wall JE, Kaste SC, Greenwald CA, et al: Fractures in children treated with radiotherapy for soft tissue sarcoma [Review]. Orthopedics 1996;19:657-664.